Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
about
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapyCombinatorial peptide libraries: mining for cell-binding peptides.Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.Dimerization of a phage-display selected peptide for imaging of αvβ6- integrin: two approaches to the multivalent effect.Synthesis and in vitro and in vivo evaluation of hypoxia-enhanced 111In-bombesin conjugates for prostate cancer imaging.A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in MiceImproved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabelingIn vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties.Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific ⁶⁴Cu-DOTA conjugation.Distinct microRNA expression profiles in mouse renal cortical tissue after 177Lu-octreotate administrationEngineering agatoxin, a cystine-knot peptide from spider venom, as a molecular probe for in vivo tumor imagingD-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodinationCancer radioimmunotherapy.Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma.The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenograftsDosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.Evaluation of retinol binding protein 4 and carbamoylated haemoglobin as potential renal toxicity biomarkers in adult mice treated with (177)Lu-octreotatePotential Biomarkers for Radiation-Induced Renal Toxicity following 177Lu-Octreotate Administration in MiceEvaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targetingIdentification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.Affibody-mediated PET imaging of HER3 expression in malignant tumours.Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.Positron emission tomography imaging of tumor angiogenesis and monitoring of antiangiogenic efficacy using the novel tetrameric peptide probe 64Cu-cyclam-RAFT-c(-RGDfK-)4.Development of copper based drugs, radiopharmaceuticals and medical materials.Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphyTargeting breast carcinoma with radioiodinated anti-HER2 NanobodyContribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate.PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules.Synthesis and pre-clinical evaluation of an (18)F-labeled single-chain antibody fragment for PET imaging of epithelial ovarian cancerSelf-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab.Radionuclide therapy via SSTR: future aspects from experimental animal studies.The inverse electron demand Diels-Alder click reaction in radiochemistry.Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.Evaluation of cytotoxic and tumor targeting capability of (177)Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapy.In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.Status and trends in the development of clinical diagnostic agents.Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.
P2860
Q28066010-9B65B5D0-A572-4764-849E-D4FAAF7EE5FCQ31144876-6B5C90FE-9BD0-4E07-A0D7-32156912C07CQ33392694-EEA9FDDB-CB75-41C8-9157-45C9D33023BEQ33686825-80AB2A19-69D7-46EB-85E8-ECABF63936D6Q33725998-0553C117-3B81-47AF-8A72-51AFFE805953Q33851549-380C3603-B2F2-4EE7-8C5A-DF0EBC32B4DCQ34148890-EDE8B6A3-85D3-4C78-9136-4733A6B9754BQ34228815-C2938CD5-CE3C-42CF-8070-6C309D393F88Q34250142-D7F9BE75-3CF2-42F4-88C8-1BA428CF88A0Q34313174-ABC82867-D68E-4875-8737-C6F6BA4F07E2Q34490021-D74724CF-C510-494A-89F6-9CA9528AFFBFQ34662001-7EF59619-C4BD-42CB-9E33-C57B49635802Q34718122-28901BB2-28F2-4E9B-A83E-3C2C9BF5EDE6Q35070045-DC107932-3E43-49EF-A3E2-13B8981B4D5BQ35287836-78D2EB07-22BF-4E63-B7E6-ED64F3E664A9Q35288474-C21B391E-EA5B-47BB-8AF9-BCAE7D70A993Q35534233-9D421B4F-84A8-4100-892B-5E3B0D62F258Q35582104-5BC84018-B246-42B0-B7E8-652E331905D4Q35675510-0AEA25EF-5EE7-4611-8E2D-5E526E876483Q35750002-BB19913E-C40E-4643-9C2B-F5D30881CAF4Q36122563-47161C57-3F20-4439-9BE7-1E9648B283CDQ36157472-252DB88A-4C96-4C77-A384-B094DA345B8EQ36174716-FBDAD758-96A2-4C4E-9432-DF363E75D2F4Q36253935-553AAB66-1712-4CF6-A391-36DAF053564CQ36394255-11A62825-2F32-44C8-B4B9-424A80149013Q36394415-E41F20BC-5C34-4EED-B87E-82F5F8220837Q36423806-1B558E4D-FA02-472A-8790-7D1638727F4CQ36552076-FCB511CB-1BB8-4447-9B34-F34D125F711AQ36564103-C0D95588-3588-4AF0-864F-881C6D109C72Q36649532-3D1BEF9D-D6DC-45D7-9266-837580E40DFAQ37136748-33203ED6-E27F-4DCB-B883-CB2032E29353Q37233043-CB729BA6-B3F5-4F83-B61F-ABBA73AAC445Q37466344-81E96477-6F1C-4425-A9CE-4DF7249AF03DQ38008839-23E86A8D-AC4D-453B-9DE2-9FF085E65E90Q38172061-411B0CEA-6E04-4A06-AD20-DE4EDA8F132CQ38739396-61C23108-B25D-462E-B9A7-D555B8D4B96AQ38792415-51D9F134-FC0F-45CB-B655-FE7EC92665FCQ38977436-BEAE1AF9-033A-46B9-AB8C-1C96D0F6F767Q38995734-F136BD9E-CBEF-4B48-8B7F-F111AD404403Q39022761-D17F5594-5224-48C9-A838-413878933DA6
P2860
Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal toxicity of radiolabeled ...... and strategies for prevention.
@en
Renal toxicity of radiolabeled ...... and strategies for prevention.
@nl
type
label
Renal toxicity of radiolabeled ...... and strategies for prevention.
@en
Renal toxicity of radiolabeled ...... and strategies for prevention.
@nl
prefLabel
Renal toxicity of radiolabeled ...... and strategies for prevention.
@en
Renal toxicity of radiolabeled ...... and strategies for prevention.
@nl
P2093
P1476
Renal toxicity of radiolabeled ...... and strategies for prevention.
@en
P2093
Jack F M Wetzels
Marion de Jong
Marleen Melis
Martin Gotthardt
Rosalinde Masereeuw
Wim J G Oyen
P304
P356
10.2967/JNUMED.110.075101
P407
P577
2010-06-16T00:00:00Z